Although breast cancer has led the way toward precision medicine, more research is still needed to increase curation rates in patients with early disease and to prolong survival with an optimal quality of life in the metastatic setting. Last year, big advances were achieved toward these goals thanks to the significant impact of immunotherapy on survival in triple-negative breast cancer and the exciting results of antibody-drug conjugates. PLAIN LANGUAGE SUMMARY: The development of new drugs and biomarkers to select those patients who will benefit of them are crucial in improving survival in breast cancer. Last year, the emergence of antibody-drug conjugates and the reaffirmation of the potential of immunotherapy in breast cancer were the most important findings.
Keywords: HER2-low; HER2-positive breast cancer; antibody-drug conjugates; immunotherapy; luminal breast cancer; triple-negative breast cancer.
© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.